4 stories this morning, for surgeons and the people who support them.
- Medacta's H1 2026: 9.7% constant-currency growth, but North America is the slowest region and gross margin fell 310 basis points — Medacta reported first-half revenue of 368 million euros, up 9.7% in constant currency, with a 27.8% adjusted EBITDA margin. North America grew 6.6%, the slowest of its four regions, which management attributed to unexpected US softening including spine channel transitions; gross margin fell 310 basis points to 65.2% and free cash flow was negative 18.6 million euros, and full-year guidance of 10 to 14% was held. Source
- ArthroTAK's sutureless PEEK anchor clears FDA for expanded indications, and its first target is lateral extra-articular tenodesis — ArthroTAK received FDA 510(k) clearance extending its sutureless PEEK tendon anchor beyond biceps tenodesis to additional anatomy, with the knee and lateral extra-articular tenodesis as the first commercial focus. The company says the implant deploys in 45 to 60 seconds and that more than 80 cases have been done in its limited biceps tenodesis release. Source
- Journal of Spine Surgery publishes cadaveric accuracy data on OnPoint's augmented reality guidance: 1.1 mm positional, 1.3 degrees angular across 80 pedicle screws — A cadaveric study in the Journal of Spine Surgery reports 1.1 mm positional and 1.3 degree angular error for 80 pedicle screws placed in five specimens by three spine surgeons using OnPoint Surgical's FDA-cleared augmented reality guidance, with no medial or inferior breaches. The paper's 2-to-5-times comparison against navigation and robotic platforms is against published figures, not a head-to-head trial. Source
- Bone Biologics doubles its Australian NB1 sites to six, aiming to finish enrollment in the rhNELL-1 TLIF pilot by year end — Bone Biologics said six Australian hospital sites are now under agreement for its first-in-human pilot of NB1, recombinant human NELL-1 on demineralized bone matrix, doubling the site count. The randomized study enrolls up to 30 adults undergoing TLIF for degenerative disc disease, with fusion success at 12 and 24 months and change in Oswestry score as endpoints, and enrollment is expected to close by the end of 2026. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.